Teva Branded Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA BRANDED PHARM, and when can generic versions of TEVA BRANDED PHARM drugs launch?
TEVA BRANDED PHARM has thirty-two approved drugs.
There are fifty-one US patents protecting TEVA BRANDED PHARM drugs.
There are seven hundred and twenty-two patent family members on TEVA BRANDED PHARM drugs in forty-two countries and thirty-nine supplementary protection certificates in fourteen countries.
Summary for Teva Branded Pharm
| International Patents: | 722 |
| US Patents: | 51 |
| Tradenames: | 32 |
| Ingredients: | 18 |
| NDAs: | 32 |
| Patent Litigation for Teva Branded Pharm: | See patent lawsuits for Teva Branded Pharm |
Drugs and US Patents for Teva Branded Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | RX | Yes | Yes | 10,188,811 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Teva Branded Pharm | QVAR 80 | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 020911-001 | Sep 15, 2000 | DISCN | Yes | No | 10,022,510 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | RX | Yes | Yes | 7,780,038 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Teva Branded Pharm | PROAIR HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 021457-001 | Oct 29, 2004 | AB2 | RX | Yes | Yes | 9,808,587 | See Plans and Pricing | Y | See Plans and Pricing | ||
| Teva Branded Pharm | QVAR 80 | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 020911-001 | Sep 15, 2000 | DISCN | Yes | No | 10,561,808 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Branded Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | PROAIR DIGIHALER | albuterol sulfate | POWDER, METERED;INHALATION | 205636-002 | Dec 21, 2018 | 8,006,690 | See Plans and Pricing |
| Teva Branded Pharm | LOXITANE C | loxapine hydrochloride | CONCENTRATE;ORAL | 017658-001 | Approved Prior to Jan 1, 1982 | 3,546,226 | See Plans and Pricing |
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | 5,776,432 | See Plans and Pricing |
| Teva Branded Pharm | PROAIR RESPICLICK | albuterol sulfate | POWDER, METERED;INHALATION | 205636-001 | Mar 31, 2015 | 6,701,917 | See Plans and Pricing |
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | 5,605,674 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA BRANDED PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 0.1 mg/0.02 mg and 0.01 mg | ➤ Subscribe | 2009-11-16 |
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg | ➤ Subscribe | 2004-03-29 |
| ➤ Subscribe | Tablets | 1 mg/0.02 mg and 75 mg | ➤ Subscribe | 2006-04-17 |
| ➤ Subscribe | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | ➤ Subscribe | 2013-07-10 |
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg/0.01 mg | ➤ Subscribe | 2008-01-22 |
International Patents for Teva Branded Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | I224513 | See Plans and Pricing |
| China | 105903113 | See Plans and Pricing |
| Eurasian Patent Organization | 037087 | See Plans and Pricing |
| Japan | 2011524784 | See Plans and Pricing |
| Japan | 2003535656 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Branded Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 300814 | Netherlands | See Plans and Pricing | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 0454511 | SPC/GB99/008 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| 1453521 | 93156 | Luxembourg | See Plans and Pricing | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| 0443983 | C00443983/03 | Switzerland | See Plans and Pricing | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| 0565634 | 06C0030 | France | See Plans and Pricing | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
